Pharmacological treatment for generalized anxiety disorder in adults: An update

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 11, 2015, Pages 1669-1681

  Reinhold, Jennifer A ^a   Rickels, Karl ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atypical antipsychotics; Benzodiazepines; Generalized anxiety disorder; Pharmacotherapy; Selective serotonin reuptake inhibitors; Serotonin norepinephrine reuptake inhibitors

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE; VORTIOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ADULT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENERALIZED ANXIETY DISORDER; HUMAN; MANAGED CARE; MEDLINE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; ANXIETY DISORDERS; OFF LABEL DRUG USE;

ADRENERGIC UPTAKE INHIBITORS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; HUMANS; OFF-LABEL USE; PIPERAZINES; SEROTONIN UPTAKE INHIBITORS; SULFIDES;

EID: 84936980931     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1059424     Document Type: Review

References (126)

1. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002;63(Suppl 14):9-16
2. Reinhold JA, Mandos LA, Rickels K, et al. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 2011;12(16):2457-67
3. Mandos L, Reinhold J, Rickels K. Achieving remission in generalized anxiety. Psychiatric Times 2009;26(2):38-41
4. Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry 2002;63(Suppl 8):11-16
5. Bandelow B, Boerner J R, Kasper S, et al. The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int 2013;110(17):300-9
6. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24-34
7. Carleton RN. The intolerance of uncertainty construct in the context of anxiety disorders: theoretical and practical perspectives. Expert Rev Neurother 2012;12(8):937-47
8. Dell'Osso B, Camuri G, Benatti B, et al. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early Interv Psychiatry 2013;7(4):374-80
9. Combs H, Markman J. Anxiety disorders in primary care. Med Clin North Am 2014;98(5):1007-23
10. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(5):355-64
11. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ 2012;345:e7500
12. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602
13. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry 2009;70(Suppl 2):4-9
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Publishing; VA, Arlington: 2000
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Publishing; VA, Arlington: 2013
16. Rickels K, Rynn MA. What is generalized anxiety disorder? J Clin Psychiatry 2001;62(Suppl 11):4-12
17. Pollack MH, Kornstein SG, Spann ME, et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 2008;42(14):1176-84
18. Bandelow B. Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 2006;11(10 Suppl 12):21-8
19. Rickels K, Rynn M, Iyengar M, et al. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006;67(1):41-7
20. Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010;67(12):1274-81
21. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 2002;63(9):756-7
22. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2007;3(2):185-91
23. Bandelow B, Sher L, Bunevicius R, et al. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessivecompulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012;16(2):77-84
24. Teff KL, Rickels MR, Grudziak J, et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013;62(9):3232-40
25. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45(5):444-50
26. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010;71(7):839-54
27. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004;161(9):1642-9
28. Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2006;67(6):874-81
29. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005;66(1):94-9
30. Baldwin D, Anderson I, Nutt D, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96
31. Stocchi F, Nordera G, Jokinen R, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003;64:250-8
32. Stocchi F, Nordera G, Jokinen RH, et al. Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003;64(3):250-8
33. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebocontrolled study. Am J Psychiatry 2003;160(4):749-56
34. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62(5):350-7
35. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the longterm treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17(2):65-9
36. Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: doubleblind, placebo controlled, flexible-dose study. Depress Anxiety 2004;19(4):234-40
37. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87(2-3):161-7
38. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006;9(5):495-505
39. Buoli M, Dell'osso B, Bosi MF, et al. Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Psychiatry Clin Neurosci 2010;64(6):612-19
40. Dahl AA, Ravindran A, Allgulander C, et al. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand 2005;111(6):429-35
41. Lenze EJ, Rollman BL, Shear MK, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA 2009;301(3):295-303
42. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, doubleblind study. Br J Psychiatry 2006;189:264-72
43. Fava GA, Gatti A, Belaise C, et al. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom 2015;84(2):72-81
44. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2012;107(5):900-8
45. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extendedrelease capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000;283(23):3082-8
46. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157(6):968-74
47. Lydiard RB. Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, doubleblind, placebo-controlled studies. Postgrad Med 1999;106(6 Suppl):17-23
48. Kim TS, Pae CU, Yoon SJ, et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci 2006;60(3):347-51
49. Bose A, Korotzer A, Gommoll C, et al. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety 2008;25(10):854-61
50. Rickels K, Etemad B, Rynn MA, et al. Remission of Generalized Anxiety Disorder after 6 months of open label tyreatment with venlafaxine XR. Psychother Psychosom 2013;82:363-71
51. Allgulander C, Nutt D, Detke M, et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 2008;22:417-25
52. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extendedrelease and placebo-controlled trial. Psychol Med 2009;39(2):267-76
53. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebocontrolled trial. Eur Neuropsychopharmacol 2008;18(9):673-81
54. Kahn RJ, McNair DM, Lipman RS, et al. Imipramine and Chlordiazepoxide in Anxiety Disorders. I. Efficacy in Anxious Outpatients. Arch Gen Psychiatry 1986;43:79-85
55. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebocontrolled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50(11):884-95
56. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. Current status of benzodiazepines. N Engl J Med 1983;309(6):354-8. (part one); 309(7):410-416(part two)
57. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(Suppl 11):53-8
58. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol 2013;27(11):967-71
59. Offidani E, Guidi J, Tomba E, et al. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 2013;82(6):355-62
60. Rickels K. Should benzodiazepines be replaced by ADs in the treatment of anxiety disorders? Fact or fiction? Psychother Psychosom 2013;82(6):351-2
61. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49(8):293-301
62. Möller HJ, Volz HP, Reimann IW, et al. Opipramol for the treatment of generalized anxiety disorder: a placebocontrolled trial including an alprazolamtreated group. J Clin Psychopharmacol 2001;21(1):59-65
63. Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry 2003;18(4):182-7
64. Feltner DE, Harness J, Brock J, et al. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DASA): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder. CNS Neurosci Ther 2009;15(1):12-18
65. Nardi AE, Valença AM, Freire RC, et al. Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res 2011;44(4):366-73
66. Nardi AE, Freire RC, Mochcovitch MD, et al. A randomized, naturalistic, parallelgroup study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol 2012;32(1):120-6
67. Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother 2014;14(11):1275-86
68. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45(5):444-50
69. Schweizer E, Rickels K, Weiss S, et al. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50(1):51-60
70. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015;72(2):136-42
71. American Psychiatric Association. Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association. American Psychiatric Pub 1990
72. Rickels K, Wiseman K, Norstad N, et al. Buspirone and diazepam in Anxiety: A controlled study. J Clin Psychiatry 1982;43(12 pt 2):81-6
73. Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry 1982;43(12 Pt 2):87-91
74. Böhm C, Robinson DS, Gammans RE. Buspirone therapy for elderly patients with anxiety or depressive neurosis. J Clin Psychiatry 1990;51(7):309
75. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 1991;105(3):428-32
76. Pecknold JC, Matas M, Howarth BG, et al. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 1989;34(8):766-71
77. Laakmann G, Schüle C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl) 1998;136(4):357-66
78. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 1998;139(4):402-6
79. Smiley A, Moskowitz H. Effects of longterm administration of buspirone and diazepam on driver steering control. Am J Med 1986;80(3B):22-9
80. Rickels K, Amsterdam Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-8
81. Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry 2004;65(Suppl 13):8-13
82. Gammans R, Stringfellow J, Hvizdos A, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A metaanalysis of eight randomized, controlled studies. Neuropsychobiology 1992;25:193-201
83. Schweizer E, Rickels K, Hassman H, et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 1998;59(4):175-83
84. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-72
85. Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008;23:18-28
86. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9
87. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-. controlled trial. Am J Psychiatry 2003;160:533-40
88. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebocontrolled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62(9):1022-30
89. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebocontrolled 8-week trial. Int Clin Psychopharmacol 2009;24(2):87-96
90. Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012;27(3):142-50
91. Montgomery S, Emir B, Haswell H, et al. Long-term treatment of anxiety disorders with pregabalin: a 1 year openlabel study of safety and tolerability. Curr Med Res Opin 2013;29(10):1223-30
92. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, doubleblind, placebo-controlled study. J Clin Psychopharmacol 2008;28(5):561-6
93. Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebocontrolled discontinuation study. J Clin Psychiatry 2012;73(7):1002-8
94. Stein DJ, Ahokas A, Márquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry 2014;75(4):362-8
95. Gommoll C, Durgam S, Mathews M, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase iii study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety 2015;32(6):451-9
96. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2009;70(3):326-33
97. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebocontrolled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72(4):441-7
98. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol 2012;27(4):197-207
99. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol 2012;22(12):847-57
100. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebocontrolled clinical trial in the United States. Eur Neuropsychopharmacol 2012;22(12):858-66
101. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, doubleblind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2. 5 and 10mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol 2014;29(1):64-72
102. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14(4):197-206
103. Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9(8):1147-58
104. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20(1):9-11
105. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005;86(1):99-104
106. Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009;24(5):265-9
107. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychopharmacol 2010;13(3):305-20
108. Stein DJ, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol 2011;26(8):614-28
109. Merideth C, Cutler AJ, She F, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 2012;27(1):40-54
110. Khan A, Joyce M, Atkinson S, et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011;31(4):418-28
111. Sheehan DV, Svedsäter H, Locklear JC, et al. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomizedwithdrawal, placebo-controlled maintenance study. J Affect Disord 2013;151(3):906-13
112. Sárvári AK, Vereb Z, Uray IP, et al. Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. Biochem Biophys Res Commun 2014;450(4):1383-9
113. Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013;42(3):545-63
114. Liao TV, Phan SV. Acute hyperglycemia associated with short-term use of atypical antipsychotic medications. Drugs 2014;74(2):183-94
115. Yan H, Chen JD, Zheng XY. Potential mechanisms of atypical antipsychoticinduced hypertriglyceridemia. Psychopharmacology (Berl) 2013;229(1):1-7
116. Canfrán-Duque A, Casado ME, Pastor O, et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 2013;54(2):310-24
117. Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013;54(1):1-13
118. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010;5(1):97-104
119. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24(1):62-9
120. Rickels K, Clark T, Ewing J, et al. Evaluation of tranquilizing drugs in medical outpatients: meprobamate, prochlorperazine, amobarbital sodium, and placebo. JAMA 1959;171(12):1649-56
121. Rickels K, Raab E, Gordon PE, et al. Differential effects of chlordiazepoxide and fluphenazine in two anxious patient populations. Psychopharmacologia 1968;12(3):181-92
122. Rickels K, Weise CC, Whalen EM, et al. Haloperidol in anxiety. J Clin Pharmacol New Drugs 1971;11(6):440-9
123. Rickels K, Hutchison J, Morris RJ, et al. Molindone and chlordiazepoxide in anxious neurotic outpatients. Curr Ther Res Clin Exp 1972;14(1):1-9
124. Rickels K, Perloff M, Perez LA, et al. Clomacran in anxious neurotic outpatients: a controlled study. J Clin Pharmacol New Drugs 1972;12(1):46-53
125. Rickels K, Weise CC, Feldman H, et al. Loxapine in neurotic anxiety: some modifiers of treatment response. J Int Med Res 1978;6(3):180-5
126. Rickels K, Gingrich RL, Csanalosi I, et al. Prochlorperazine, chlordiazepoxide and placebo in anxious outpatients. Curr Ther Res 1981;29:156-64